Methods For Treating Alzheimer's Disease or Dementia Using A Calcilytic And A Calcimimetic
OwnerWenhan Chang, Chia-Ling Tu +1inventors
InventorsWenhan Chang, Chia-Ling Tu, James Koh
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating or preventing Alzheimer's disease or dementia and concurrently treating hyperparathyrodism by administering a blood-brain barrier (BBB)-impermeable calcimimetic and/or a BBB-permeable calcilytic along with the administration of anti-amyloid-beta therapies. Also disclosed herein are methods of increasing calcium-sensing receptor (CaSR) homodimer formation, increasing expression or activity of the CaSR homodimer and reducing CaSR/GABA-B1 receptor heterodimer formation, reducing expression or activity of the CaSR/GABA-B1 receptor heterodimer in both peripheral tissues and central nervous system (CNS) in a subject.
Claims26
A method of treating Alzheimer's disease or dementia in a subject, the method comprising administering to the subject a therapeutically effective amount of a blood-brain barrier (BBB)-impermeable calcimimetic or a blood-brain barrier-permeable calcilytic, thereby treating or preventing Alzheimer's disease or dementia in the subject.
A method of increasing calcium-sensing receptor (CaSR) homodimer formation, increasing expression or activity of a calcium-sensing receptor (CaSR) homodimer or blocking CaSR/GABA-B1 receptor heterodimer formation in both peripheral tissues and the central nervous system (CNS) in a subject, the method comprising administering to the subject a therapeutically effective amount of a blood-brain barrier (BBB)-impermeable calcimimetic and a calcilytic, thereby increasing calcium-sensing receptor (CaSR) homodimer formation, increasing expression or activity of CaSR homodimer or blocking CaSR/GABA-B1 receptor heterodimer formation in peripheral tissues and the CNS, respectively in the subject.
A method of reducing or blocking CaSR/GABA-B1 receptor heterodimer activity in a subject, the method comprising administering to the subject a therapeutically effective amount of a blood-brain barrier (BBB)-impermeable calcimimetic and a calcilytic, thereby reducing or blocking CaSR/GABA-B1 receptor heterodimer activity in the subject.
(canceled)
-12. (Canceled)
-23. (canceled)
(canceled)
(canceled)
(canceled)
-37. (canceled)
Dependencies are inferred from the claim text.